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tIn patients with aplastic anemia (AA), allogeneic
tem cell transplantation (ASCT) is the treatment of
hoice for younger patients with HLA-matched sib-
ings. In patients older than 40 years, transplant-re-
ated mortality approaches 50% and survival does not
iffer between patients who receive ASCT and those
ho receive immunosuppressive therapy [1]. In this
ge group, immunosuppressive therapy has been ad-
ocated as upfront therapy, with ASCT offered only
or failed immunosuppressive therapy or relapse [2].
owever, this approach gives rise to 2 major concerns:
longer interval from diagnosis to transplantation and
n increase in the number of transfusions received.
oth factors have been recognized as adverse risk
redictors for inferior outcomes in patients undergo-
ng ASCT for AA. The recent introduction of less
ntense nonmyeloablative (NM) conditioning regi-
ens has not only resulted in lower transplant-
elated mortality but also widened the age range of
otential recipients suitable for transplantation and
ncludes those who are less medically ﬁt [3]. We
eport our preliminary experience with the use of an
M preparative regimen for ASCT in 8 patients
ith severe AA.
Between November 2000 and October 2005, 8
atients (median age, 43 years; age range, 25-48 years)
ith acquired, very severe AA (n  4) or severe AA
n  4) were enrolled in a treatment protocol that was
pproved by the ethics committee of Singapore Gen-
ral Hospital. Written informed consent was obtained
n all cases. Patient and treatment characteristics are
isted in Table 1.
Unmanipulated ﬁlgrastim-mobilized peripheral
lood stem cells at a median cell dose of 6.56 106/kg
D34 cells (range, 3.34-22.89  106/kg) were in-
used into recipients after a conditioning regimen that
as adapted from McSweeney et al [3], which con-
isted of ﬂudarabine 30 mg/m2 (days 4 to 2) and
otal body irradiation 2 Gy (day 0). Acute graft-versus-
ost disease (GVHD) prophylaxis consisted of cyclo-
porine 6.25 mg/kg twice daily from day 3 to day o100, followed by a taper until day 180; mycophe-
olate mofetil 15 mg/kg twice daily from day 0 to day
50, with a subsequent taper to day 100; and a short
ourse of intravenous methotrexate (MTX; 15 mg/m2
n day 1, 10 mg/m2 on days 3, 6, and 11) for
ll but the ﬁrst 2 patients (patients 1 and 2), who were
iven only cyclosporine and mycophenolate mofetil.
The conditioning regimen was well tolerated in all
atients, with no grade 3 or 4 regimen-related mu-
ositis, nausea, vomiting, diarrhea, veno-occlusive dis-
ase of the liver, hemorrhagic cystitis, or cardiac or
ulmonary toxicity seen (National Cancer Institute
ommon toxicity criteria) [4]. All patients achieved
rompt and sustained engraftment (Table 2). Median
ime to a neutrophil count .5  109/L was 18 days
range, 13-21 days), and median time to an unsup-
orted platelet count 20  109/L was 13 days
range, 8-25 days). Red blood cell and platelet trans-
usion independence were achieved in evaluable pa-
ients at medians of 8 days (range, 1-17 days) and 10
ays (range, 6-20 days), respectively. Chimerism anal-
sis on day 28 showed mixed chimerism (87.5%-
5%) in all patients. This mixed chimerism persisted
t 3-6 months after transplantation in 6 surviving
atients, with 4 of these patients achieving full donor
himerism by 6-12 months. No secondary graft failure
as seen.
Grade 2-4 acute GVHD was observed in 3 pa-
ients (2 with grade 3 and 1 with grade 2). The 2
atients (patients 1 and 2) who did not receive MTX
s GVHD prophylaxis developed grade 3 acute
VHD, leading to subsequent invasive fungal infec-
ions and death. Chronic GVHD was observed in 3
atients (2 with limited and 1 with extensive GVHD),
ncluding 1 patient who received an allograft from a
atched unrelated donor, and all responded to cal-
ineurin inhibitors.
With a median follow-up of 24 months (range,
-52 months), all 6 patients who received MTX-con-
aining GVHD prophylaxis are alive, are independent
f transfusion, and have Karnofsky performance
887
Table 1. Baseline Characteristics, Grafts, and GVHD Prophylaxis of 8 Patients with AA*
Patient
No. Diagnosis Donor
D/R Age
(y)
D/R
Gender
Time from Diagnosis
to HSCT (mo) Prior Therapy
CD34 Dose
Infused
(106/kg)
MNC Dose
Infused
(108/kg)
GVHD
Prophylaxis
D/R CMV
Status
1 SAA Matched sibling 49/48 M/F 2 No 6.56 16.14 CSP/MMF /
2 SAA Matched sibling 34/47 M/F 60 ATG/CSP 3.34 34.37 CSP/MMF /
3 SAA Matched sibling 42/46 F/M 6 ATG/CSP 11.46 8.24 CSP/MMF/MTX /
4 vSAA Matched sibling 27/35 F/M 3 No 5.27 8.79 CSP/MMF/MTX /
5 vSAA Matched unrelated 25/43 M/F 6 CSP, GCSF, erythropoietin,
oxymetholone
5.9 9.08 CSP/MMF/MTX /
6 vSAA Matched sibling 55/46 M/F 2 No 6.65 20.25 CSP/MMF/MTX /
7 vSAA Matched sibling 27/25 F/M 1 No 22.89 6.40 CSP/MMF/MTX NA
8 PNH with
SAA
Matched sibling 24/26 F/F 3 No 7.30 13.33 CSP/MMF/MTX /
*NA indicates data not available; F, female; M, male; D, donor; R, recipient; HSCT, hematopoietic stem cell transplant; SAA, severe aplastic anemia; vSAA, very severe aplastic anemia; PNH, paroxysmal
nocturnal hemogloblinuria; MNC, mononuclear cells; GVHD, graft–versus-host disease; CSP, cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate; CMV, cytomegalovirus; GCSF,
granulocyte colony-stimulating factor; ATG, antithymocyte globulin.
Table 2. Clinical Outcome of 8 Patients with AA Undergoing NM Transplantation*
Patient
No.
Days to Neutrophil
Count >0.5  109/L
Days to Platelet
Count >20  109/L
Infective
Complications
Within 100 Days
aGVHD
Grade/Site cGVHD Current Status Cause of Death
Final Chimerism
Studies
1 Never† 12 Fungal pneumonia 3/liver — Dead, day 70 Invasive fungal
infection
100% on day 56
2 Never† 15 Disseminated fungal
infections
3/liver — Dead, day 64 Invasive fungal
infection
100% on day 56
3 16 13 No 1/gut No Alive, day 1546 — 100% at 3 y
4 19 19 CMV antigenemia No Limited/skin Alive, day 1343 — 100% at 3 y
5 15 13 No No Limited/skin Alive, day 753 — 100% at 2 y
6 16 12 CMV antigenemia No No Alive, day 657 — 100% at 18 mo
7 21 21 CMV antigenemia 2/gut Extensive/
oral/skin
Alive, day 516 — 100% at 15 mo
8 21 12 No No NE‡ Alive, day 132 — 87.5% at 3 mo
*aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; CMV, cytomegalovirus.
†Neutrophil count never decreases to .5  109/L.
‡Not evaluable for cGVHD.
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Letter to the Editor 889cores 90%. Four of the matched sibling recipients
nd 1 unrelated donor allograft recipient maintained
ull donor chimerism during the ﬁnal follow-up. One
atient (patient 8) with paroxysmal nocturnal hemo-
lobinuria had sustained engraftment with mixed chi-
erism (87.5% donor chimerism) and no detectable
aroxysmal nocturnal hemoglobinuria clone by ﬂuo-
escence-activated cell sorting determination of CD55
nd CD59 at 4 months’ follow-up.
The feasibility of ASCT using an NM preparative
egimen in AA remains to be established, mainly due
o concerns of a high risk of graft rejection, in partic-
lar among patients who receive multiple transfusions.
he results seen in this small cohort of patients have
ighlighted several important points. (1) This minimal
onditioning regimen was sufﬁciently immunosup-
ressive in allowing prompt and stable engraftment
mong patients with AA. (2) It was associated with
inimal toxicity, with no patients developing early
rade 3 regimen-related toxicity, which had been
een in patients after conditioning with cyclophosph-
mide and antithymocyte globulin [5]. This is poten-
ially beneﬁcial in allowing transplantation to be per-
ormed in the outpatient setting. (3) This approach
lso avoids the use of T-cell–depleting agents such as
ntithymocyte globulin or alemtuzumab. Omission of
hese T-cell–depleting agents may have resulted in a
ore rapid post-transplantation immune reconstitu-
ion and reduction of infections such as cytomegalo-
irus (CMV). Three of 8 patients developed CMV
ntigenemia with no observed CMV disease. This
nding compares favorably with other alemtuzumab-
r antithymocyte globulin–based NM transplant se-
ies, which reported CMV infection rates that ex-
eeded 50% [6,7]. (4) Addition of MTX into the
VHD prophylaxis regimen could account for the
ore favorable outcome, with no fatal GVHD seen
mong the 6 patients who received the MTX-contain-
ng GVHD prophylaxis. (5) Five of the 8 patients
63%) in this series were 40 years old at the time of
ransplantation, and 3 of these patients remained dis-
ase free and alive at 20 months’ follow-up. These
ncouraging results provide a rationale for conduct-
ng larger studies with this less intensive condition-
ng regimen as upfront therapy in older patients or
atients who have comorbidities precluding high-
ose cyclophosphamide conditioning.
The uniform and durable engraftment in the cur-
ent 8 multiply transfused patients is encouraging.
his is partly attributed to the use of peripheral blood
tem cells that contained a higher CD34 cell dose
nd approximately 10-fold the number of T cells.
owever, reservations remain with the use of periph-
ral blood stem cells because of the increased risk of
hronic GVHD, although a recent report has quoted
low incidence of 26% chronic GVHD when using
imilar approach in patients with AA [8]. Clearly, Hmproved GVHD control remains a critical future
esearch objective. Optimizing immunosuppression
y prolonging cyclosporine therapy and dose-adapted
ycophenolate mofetil might be a promising way to
ecrease GVHD [9].
In conclusion, our results suggest that ASCT us-
ng an NM conditioning regimen results in stable
ngraftment and favorable outcome in patients with
A, including patients who are 40 years old and
hose who receive unrelated allografts. These prom-
sing results, although based on a small number of
atients, merit further investigation and conﬁrmation
n a larger cohort of patients with longer follow-up.
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